Folimycin (concanamycin A) inhibits LPS-induced nitric oxide production and reduces surface localization of TLR4 in murine macrophages

Abstract

Lipopolysaccharide (LPS) is a major cell wall component of Gram-negative bacteria and signals through a receptor complex which consists of TLR4, MD-2 and CD14. LPS signaling in macrophages induces the production of many pro-inflammatory molecules, including nitric oxide (NO). In this study, we have shown that folimycin, a macrolide antibiotic and a specific inhibitor of vacuolar ATPase (V-ATPase), inhibits LPS-induced NO production, but not TNFα production, in murine elicited peritoneal macrophages. However, folimycin did not affect interferon-γ induced NO production. LPS-induced iNOS mRNA and protein expression and NF-κB activation were also inhibited by folimycin. Interestingly, folimycin-treated cells showed reduced surface expression of TLR4 molecules and dilated Golgi apparatus. These findings suggest that folimycin, by inhibiting V-ATPases, alters intra-Golgi pH, which in turn causes defective processing and reduced surface expression of TLR4 reducing the strength of LPS signaling in murine macrophages.

Keywords

Folimycin LPS Nitric oxide TLR4

References

Annane D. , Bellissant E. , Cavaillon J-M. Septic shock. Lancet 2005; 365: 63—78.

Medzhitov R. , Preston-Hurlburt P. , Janeway Jr CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity . Nature 1997; 388: 394—397.

Poltorak A. , He X. , Smirnova I. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085—2088.

Wright SD , Ramos RA , Tobias PS , Ulevitch RJ , Mathison JC CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431—1433.

Shimazu R. , Akashi S. , Ogata H. et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189: 1777—1782.

Nagai Y. , Akashi S. , Nagafuku M. et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution . Nat Immunol 2002; 3: 667—672.

Hoshino K. , Takeuchi O. , Kawai T. et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749—3752.

Alderton WK , Cooper CE , Knowles RG Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593—615.

Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004; 75: 639—653.

10.

Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907—916.

11.

Fitzgerald KA , Chen ZJ Sorting out Toll signals. Cell 2006; 125: 834—836.

12.

Hayden MS , West AP , Ghosh S. NF-kappaB and the immune response. Oncogene 2006; 25: 6758—6780.

13.

Drose S. , Bindseil KU , Bowman EJ , Siebers A. , Zeeck A. , Altendorf K. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosine triphosphatases. Biochemistry 1993 ; 32: 3902—3906.

14.

de Bouteiller O. , Merck E. , Hasan UA et al. Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem 2005; 280: 38133—38145.

15.

Lee J. , Chuang TH , Redecke V. et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003; 100: 6646—6651.

16.

Rutz M. , Metzger J. , Gellert T. et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 2004 ; 34: 2541—2550.

17.

Yilla M. , Tan A. , Ito K. , Miwa K. , Ploegh HL Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells. J Biol Chem 1993; 268: 19092—19100.

18.

Weisz OA Acidification and protein traffic. Int Rev Cytol 2003; 226: 259—319.

19.

Mellman I. , Fuchs R. , Helenius A. Acidification of the endocytic and exocytic pathways. Annu Rev Biochem 1986; 55: 663—700.

20.

Muroi M. , Shiragami N. , Nagao K. , Yamasaki M. , Takatsuki A. Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus. Cell Struct Funct 1993; 18: 139—149.

21.

Muroi M. , Takasu A. , Yamasaki M. , Takatsuki A. Folimycin (concanamycin A), an inhibitor of V-type H(+)-ATPase, blocks cell-surface expression of virus-envelope glycoproteins. Biochem Biophys Res Commun 1993; 193: 999—1005.

22.

Green LC , Wagner DA , Glogowski J. , Skipper PL , Wishnok JS , Tannenbaum SR Analysis of nitrate, nitrite, and [15N]-nitrate in biological fluids . Anal Biochem 1982; 126: 131—138.

23.

Muroi M. , Shiragami N. , Takatsuki A. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun 1994; 205: 1358—1365.

24.

Hong J. , Nakano Y. , Yokomakura A. et al. Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells. J Pharmacol Exp Ther 2006; 319: 672—681.

25.

Drouet C. , Shakhov AN , Jongeneel CV Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-alpha promoter in primary macrophages. J Immunol 1991; 147: 1694—1700.

26.

Seog DH SS33410, an inhibitor of V-ATPase, blocks intracellular protein transport of the VSV-G protein in the Golgi compartment. Biosci Biotechnol Biochem 2003; 67: 2591—2597.

27.

Seog DH , Yamasaki M. , Takatsuki A. SS33410, an inhibitor for inflammation, blocks the intracellular transport of VSV G glycoprotein in BHK cells. Biochem Biophys Res Commun 1994; 199: 1073—1080.

28.

Akashi S. , Shimazu R. , Ogata H. et al. Cell surface expression and lipopolysaccharide signaling via the Toll-like receptor 4—-MD-2 complex on mouse peritoneal macrophages . J Immunol 2000; 164: 3471—3475.

29.

Nomura F. , Akashi S. , Sakao Y. et al. Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression. J Immunol 2000; 164: 3476—3479.

30.

Gustafson CE , Katsura T. , McKee M. , Bouley R. , Casanova JE , Brown D. Recycling of AQP2 occurs through a temperature- and bafilomycin-sensitive trans-Golgi-associated compartment. Am J Physiol 2000; 278: F317—F326.

31.

Palokangas H. , Metsikko K. , Vaananen K. Active vacuolar H+-ATPase is required for both endocytic and exocytic processes during viral infection of BHK-21 cells . J Biol Chem 1994; 269: 17577—17585.

32.

Robinson DG , Albrecht S. , Moriysu Y. The V-ATPase inhibitors concanamycin A and bafilomycin A lead to Golgi swelling in tobacco BY-2 cells . Protoplasma 2004; 224: 255—260.

33.

Zhang X. , Morrison DC Lipopolysaccharide-induced selective priming effects on tumor necrosis factor α and nitric oxide production in mouse peritoneal macrophages. J Exp Med 1993; 177: 511—516.

34.

Zhang X. , Morrison DC Pertussis toxin-sensitive factor differentially regulates lipopolysaccharide-induced tumor necrosis factor-alpha and nitric oxide production in mouse peritoneal macrophages. J Immunol 1993; 150: 1011—1018.

35.

Hirohashi N. , Lei MG , Morrison DC LPS pretreatment of mouse peritoneal macrophages differentially modulates TNF-α and iNOS expression . J Endotoxin Res 1999; 5: 251—260.

36.

Goldfeld AE , Doyle C. , Maniatis T. Human tumor necrosis factor α gene regulation by virus and lipopolysaccharide. Proc Natl Acad Sci USA 1990; 87: 9769—9773.

37.

Haas JG , Baeuerle PA , Riethmuller G. , Ziegler-Heitbrock HWL. Molecular mechanisms in down-regulation of tumor necrosis factor expression . Proc Natl Acad Sci USA 1990; 87: 9563—9567.

38.

Schapiro FB , Grinstein S. Determinants of the pH of the Golgi complex . J Biol Chem 2000; 275: 21025—21032.

39.

Presley JF , Mayor S. , McGraw TE , Dunn KW , Maxfield FR Bafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling. J Biol Chem 1997; 272: 13929—13936.

40.

Tawfeek HA , Abou-Samra AB Important role for the V-type H(+)-ATPase and the Golgi apparatus in the recycling of PTH/PTHrP receptor. Am J Physiol 2004; 286: E704—E710.

41.

Palokangas H. , Ying M. , Vaananen K. , Saraste J. Retrograde transport from the pre-Golgi intermediate compartment and the Golgi complex is affected by the vacuolar H+-ATPase inhibitor bafilomycin A1. Mol Biol Cell 1998; 9: 3561—3578.

42.

Johnson LS , Dunn KW , Pytowski B. , McGraw TE Endosome acidification and receptor trafficking: bafilomycin A1 slows receptor externalization by a mechanism involving the receptor's internalization motif . Mol Biol Cell 1993; 4: 1251—1266.

43.

da Silva Correia J. , Ulevitch RJ MD-2 and TLR4 N-linked glycosylations are important for a functional lipopolysaccharide receptor. J Biol Chem 2002; 277: 1845—1854.

44.

Ohnishi T. , Muroi M. , Tanamoto K. N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for Toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide . J Immunol 2001; 167: 3354—3359.

45.

Stelter F. , Pfister M. , Bernheiden M. et al. The myeloid differentiation antigen CD14 is N- and O-glycosylated. Contribution of N-linked glycosylation to different soluble CD14 isoforms . Eur J Biochem 1996; 236: 457—464.

46.

Kellokumpu S. , Sormunen R. , Kellokumpu I. Abnormal glycosylation and altered Golgi structure in colorectal cancer: dependence on intra-Golgi pH. FEBS Lett 2002; 516: 217—224.

47.

Annane D. , Sanquer S. , Sebille V. et al. Compartmentalised inducible nitric-oxide synthase activity in septic shock. Lancet 2000; 355: 1143—1148.

48.

Han X. , Fink MP , Yang R. , Delude RL Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice. Shock 2004 ; 21: 261—270.

49.

Nava E. , Palmer RM , Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial ? Lancet 1991; 338: 1555—1557.

50.

Lopez A. , Lorente JA , Steingrub J. et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32: 21—30.